176 related articles for article (PubMed ID: 18082825)
1. Re: Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer s. P. Lerner, C. M. Tangen, H. Sucharew, D. Wood and E. D. Crawford J Urol 2007; 177: 1727-1731.
Lamm DL
J Urol; 2008 Feb; 179(2):788. PubMed ID: 18082825
[No Abstract] [Full Text] [Related]
2. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
3. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
[TBL] [Abstract][Full Text] [Related]
4. Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Palou J; Rodríguez O; Segarra J; Rosales A
J Urol; 2006 Jul; 176(1):407; author reply 407-8. PubMed ID: 16753451
[No Abstract] [Full Text] [Related]
5. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
Aldemir M; Canda AE; Balbay MD
Eur Urol; 2010 Aug; 58(2):e23; author reply e24-5. PubMed ID: 20542629
[No Abstract] [Full Text] [Related]
6. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
Raj GV; Herr H; Serio AM; Donat SM; Bochner BH; Vickers AJ; Dalbagni G
J Urol; 2007 Apr; 177(4):1283-6; discussion 1286. PubMed ID: 17382713
[TBL] [Abstract][Full Text] [Related]
7. Re: can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? H. W. Herr, S. M. Donat and G. Dalbagni J Urol 2007; 177: 75-79.
Nieder AM; Soloway MS; Jewett MA
J Urol; 2007 Jul; 178(1):352. PubMed ID: 17507038
[No Abstract] [Full Text] [Related]
8. Is maintenance Bacillus Calmette-Guérin really necessary?
Herr HW
Eur Urol; 2008 Nov; 54(5):971-3. PubMed ID: 18585842
[No Abstract] [Full Text] [Related]
9. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
10. Management of BCG failures in superficial bladder cancer: a review.
Witjes JA
Eur Urol; 2006 May; 49(5):790-7. PubMed ID: 16464532
[TBL] [Abstract][Full Text] [Related]
11. Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study: T. Cai, G. Nesi, G. Tinacci, E. Zini, N. Mondaini, v. Boddi, s. Mazzoli and R. Bartoletti J Urol 2008; 180: 110-115.
Sylvester RJ; Oosterlinck W; O'Donnell M
J Urol; 2009 Jan; 181(1):410. PubMed ID: 19010500
[No Abstract] [Full Text] [Related]
12. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K
Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
[TBL] [Abstract][Full Text] [Related]
13. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Portillo J; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Montesinos M; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA
J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
[TBL] [Abstract][Full Text] [Related]
14. Re: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder.
Klotz L
J Urol; 2000 Nov; 164(5):1666. PubMed ID: 11025741
[No Abstract] [Full Text] [Related]
15. Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues.
Sylvester RJ
Eur Urol; 2009 Aug; 56(2):266-8; discussion 268-9. PubMed ID: 19427110
[No Abstract] [Full Text] [Related]
16. Tumor associated macrophages: predicting bacillus Calmette-Guerin immunotherapy outcomes.
Brandau S
J Urol; 2009 Apr; 181(4):1532-3. PubMed ID: 19230928
[No Abstract] [Full Text] [Related]
17. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy.
Herr HW
Urology; 2007 Jul; 70(1):65-8. PubMed ID: 17656210
[TBL] [Abstract][Full Text] [Related]
18. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?
Dalbagni G
Eur Urol; 2009 Aug; 56(2):257-8; discussion 258-9. PubMed ID: 19427109
[No Abstract] [Full Text] [Related]
19. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours.
Lebret T; Watson RW; Molinié V; Poulain JE; O'Neill A; Fitzpatrick JM; Botto H
Eur Urol; 2007 Jan; 51(1):161-6; discussion 166-7. PubMed ID: 16828965
[TBL] [Abstract][Full Text] [Related]
20. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
Lamm D; Böhle A; Palou J; Persad R; Brausi M; Colombel M; Akaza H; Buckley R
Eur Urol; 2010 Feb; 57(2):e7-9; author reply e10-1. PubMed ID: 19914768
[No Abstract] [Full Text] [Related]
[Next] [New Search]
